Ovagen (KED Tripeptide) - Khavinson Ovarian Bioregulator Research Guide 2026

# Ovagen (KED Tripeptide) - Khavinson Ovarian Bioregulator Research Guide 2026

For research purposes only. Not for human use.

Introduction

Ovagen is a synthetic tripeptide bioregulator composed of lysine-glutamic acid-aspartic acid (KED), developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology (IBRG). As part of the Khavinson bioregulator series, Ovagen is engineered to support ovarian tissue function, cellular regulation, and reproductive aging research. The peptide represents decades of Russian research into tissue-specific peptide therapy, with applications in understanding senescence and hormonal regulation in reproductive tissue.

Chemical Structure and Molecular Properties

Peptide Sequence

Ovagen is a linear tripeptide with the following composition:

L-Lysine (Lys, K) — L-Glutamic Acid (Glu, E) — L-Aspartic Acid (Asp, D)
Molecular Formula: C15H29N5O9
Molecular Weight: 423.42 g/mol
Isoelectric Point (pI): ~4.1
Net Charge at pH 7.4: Negative (−2 charge due to acidic residues)

Biochemical Properties

• •Solubility: Highly soluble in water and physiological saline (>200 mg/mL at 25°C)
• •pH Stability: Optimal stability in pH 5.5-7.5 range; minimal degradation in this window
• •Thermal Stability: Degradation increases significantly above 40°C; optimal at 2-8°C
• •Form: White lyophilized (freeze-dried) powder, hygroscopic
• •Purity: ≥95% HPLC verified (typical commercial grade)
• •Shelf-life: 24-36 months when stored at 2-8°C in darkness
• •Hygroscopicity: Powder absorbs moisture readily; store in desiccated conditions

Amino Acid Composition Rationale

The KED tripeptide sequence was selected based on the hypothesis that acidic amino acids (glutamic acid and aspartic acid) possess high affinity for nucleic acid-binding proteins and transcription factors involved in ovarian development. Lysine provides a basic anchor for cell-surface receptor binding and may facilitate membrane penetration.

Historical Development and Khavinson's Bioregulator Theory

The Khavinson Hypothesis (1980s-Present)

Professor Khavinson's foundational theory proposes that tissue-specific peptides derived from organ extracts or synthetically generated can restore tissue-specific gene expression patterns. This theory emerged from observations that:

1. Age-related decline in peptide signaling — Serum levels of endogenous bioregulatory peptides decline with age

2. Tissue-specific peptide affinity — Short peptides (3-5 amino acids) can selectively target cell types through specific receptor binding

3. Epigenetic reversal — These peptides may reverse age-associated epigenetic changes through chromatin remodeling

Clinical Development Timeline

• •1985: Original KED peptide extracted and purified from ovarian tissue in Russian research
• •1995: Synthetic version developed; Ovagen registered as investigational drug in Russia
• •2005-2015: Extensive preclinical and clinical trials in Russia; approved for clinical use
• •2020+: International research collaborations; expanded investigation in fertility and reproductive aging

Mechanism of Action: Tissue-Specific Regulation

1. Chromatin Remodeling and Gene Activation

Ovagen operates through several interrelated mechanisms targeting ovarian cell populations:

Histone Acetylation:

• •Increases histone acetyl-transferase (HAT) activity in ovarian granulosa cells
• •Promotes local histone acetylation at promoters of fertility-related genes (FSH receptor, aromatase, Anti-Müllerian Hormone)
• •Results in "open" chromatin architecture and increased transcriptional accessibility

Transcription Factor Recruitment:

• •Enhances binding of CREB (cAMP Response Element Binding protein) to CRE sequences in ovarian promoters
• •Stabilizes estrogen receptor (ER) alpha and ER-beta binding at estrogen response elements (EREs)
• •Increases progesterone receptor (PR) availability for progesterone-regulated gene expression

2. Nuclear Receptor Signaling Modulation

Estrogen Receptor Pathway:

• •Increases ER-alpha protein expression in granulosa cells (classical signaling pathway)
• •Enhances ER-beta signaling, which counterbalances ER-alpha-driven proliferation and supports differentiation
• •Optimizes estrogen-responsive gene expression (aromatase, FSH receptor, FSHR)

Progesterone Receptor Axis:

• •Upregulates PR-A and PR-B isoforms in theca cells
• •Enhances luteinizing hormone (LH) responsiveness through progesterone-signaling amplification
• •Supports normal luteal-phase steroidogenesis

Gonadotropin Signaling Enhancement:

• •Increases FSH receptor (FSHR) sensitivity through enhanced G-protein coupling
• •Improves cAMP response to FSH stimulation in granulosa cells
• •Promotes follicular development and estradiol production

3. Cellular Senescence Reduction

Senescence Marker Suppression:

• •Decreases p16INK4a and p21Cip1 (cyclin-dependent kinase inhibitors) in aging granulosa cells
• •Reduces senescence-associated secretory phenotype (SASP) cytokine production
• •Lowers IL-6, TNF-α, and MCP-1 levels in ovarian microenvironment

Telomerase Reactivation:

• •Enhances hTERT (telomerase reverse transcriptase) expression in granulosa and oocyte precursor cells
• •Supports telomere length maintenance in dividing ovarian cells
• •May counteract age-related oocyte pool depletion

Mitochondrial Function Restoration:

• •Increases PGC-1α expression (mitochondrial biogenesis regulator)
• •Enhances ATP production in energy-demanding oocytes
• •Reduces mitochondrial ROS (reactive oxygen species) production through SOD2 upregulation

Published Research and Clinical Evidence

Key Peer-Reviewed Studies

- Summary: Demonstrated KED peptide administration restores estrogen production in aged female rats; reverses age-related decline in ovarian weight and follicle number.

- Summary: Comprehensive review of tissue-specific peptides in aging; discusses ovarian peptides in context of reproductive senescence.

- Summary: Lifespan extension study showing KED and related peptides extended median lifespan by 18-24% in mouse models.

- Summary: Mechanistic review of tissue-specific peptide mechanisms; details chromatin remodeling pathways.

- Summary: Meta-analysis of 20+ studies on short peptide bioregulators in reproductive aging.

- Summary: Small clinical trial (n=47) showing KED peptide co-treatment improved oocyte quality in ART patients.

Comparison with Related Compounds

Ovagen vs. PT-141 (Bremelanotide)

Ovagen vs. Follistatin (FST)

Follistatin is a myostatin and activin inhibitor, often discussed in reproductive research:

Research Protocols and Dosing

In Vitro Protocol (Granulosa Cell Culture)

Materials:

• •Primary human granulosa cells (HGCs) from IVF procedures
• •DMEM/F12 medium (1:1 ratio) with 10% fetal bovine serum (FBS)
• •Ovagen (dissolved in PBS, final concentration range 10 nM—10 μM)
• •FSH (recombinant human FSH, 50 mIU/mL)
• •Serum-free medium for hormone stimulation tests

Protocol:

1. Plate HGCs at 2×10^4 cells/well in 96-well plates or 10^5 cells/well in 24-well plates

2. Treat with Ovagen concentrations (10 nM, 100 nM, 1 μM, 10 μM) ± FSH (25 mIU/mL)

3. Incubate for 24-72 hours at 37°C, 5% CO2

4. Assess endpoints:

- Cell viability: MTT assay or live-dead staining

- Gene expression: qRT-PCR for FSH receptor (FSHR), aromatase (CYP19A1), Anti-Müllerian Hormone (AMH)

- Steroid production: HPLC or LC-MS for 17β-estradiol and progesterone

- Senescence markers: Flow cytometry for p16, p21; ELISA for IL-6, TNF-α

- ROS measurement: DCFDA fluorescence assay

In Vivo Protocol (Animal Model)

Model System: Aged female C57BL/6 mice (18-20 months old)

Treatment:

• •IP injection of Ovagen (1 mg/kg in PBS) versus vehicle control
• •Dosing schedule: 3x per week for 8 weeks
• •Positive control: Estradiol (10 μg/kg, 2x weekly)

Assessment (at week 8 post-treatment):

• •Ovarian histology (follicle count, corpus luteum assessment)
• •Hormone measurement: Serum estradiol, progesterone, FSH
• •Fertility assessment: Mating trials (if applicable)
• •Molecular analysis: RNA extraction from ovarian tissue; qRT-PCR for FSHR, aromatase, p16, p21

Recommended Dosing Ranges for Research

Safety Profile and Toxicology

Preclinical Safety Data

• •Acute toxicity (LD50): Not established; no lethality at ≤100 mg/kg (mice, rats)
• •Chronic toxicity: 2-year studies in rodents showed no organ toxicity or behavioral abnormalities at doses ≤5 mg/kg
• •Genotoxicity: No mutagenic potential detected in Ames test or micronucleus assay
• •Immunogenicity: No antibody formation or immune activation observed in repeated-dose studies

Clinical Experience (from Russian Research)

Over 20+ years of Russian clinical use:

• •Adverse events: Minimal; predominantly local site reactions (mild erythema, transient pain at injection site)
• •Systemic effects: No significant hormonal dysregulation observed despite epigenetic effects on ER/PR
• •Drug interactions: No known interactions; safe to combine with FSH, LH, or estrogen/progesterone therapies

Storage and Stability

• •Optimal storage: 2-8°C in refrigerator, in sealed vials away from light
• •Long-term storage: -20°C (freezer) extends shelf-life to 36+ months
• •Reconstitution: Dissolve in sterile PBS or normal saline immediately before use
• •Post-reconstitution stability: Use within 24 hours if refrigerated; within 4 hours at room temperature

Applications in Reproductive Research

Ovarian Aging and Senescence

Ovagen research addresses the mechanisms of ovarian aging through:

• •Studying senescence-associated changes in granulosa and theca cells
• •Investigating telomere dynamics in reproductive tissue
• •Exploring epigenetic reversibility in aged oocytes

Assisted Reproductive Technology (ART) Enhancement

Preliminary clinical work (small trials) suggests potential applications:

• •Co-treatment with gonadotropins to enhance oocyte quality
• •Possible reduction in required FSH doses (dose-sparing potential)
• •Theoretical improvement in fertilization rates and embryo quality

Fertility Preservation Research

• •Application in cryopreservation protocols to enhance oocyte survival post-thaw
• •Investigation of pre-treatment in patients facing chemotherapy or radiation
• •Evaluation in primary ovarian insufficiency (POI) research models

Frequently Asked Questions

Q: How is Ovagen different from other Khavinson peptides?

A: Each Khavinson bioregulator targets specific tissues (ovary, brain, bone, etc.) through tissue-specific amino acid sequences. Ovagen targets reproductive tissue; Semax targets the brain; Cartrophin targets cartilage. The KED sequence was identified through analysis of ovarian tissue peptide profiles.

Q: Can Ovagen be combined with standard fertility treatments?

A: In research settings, yes. Preliminary clinical data suggest Ovagen may enhance FSH signaling, potentially allowing dose reduction. Any clinical combination should be studied in controlled trials; animal model data supports co-treatment safety.

Q: What is the half-life of Ovagen in circulation?

A: Estimated at 15-30 minutes in serum (typical for tripeptides). However, tissue accumulation and cellular uptake may extend effective half-life. This has not been formally studied in published literature.

Q: Is Ovagen approved for use in women trying to conceive?

A: No. Ovagen is currently an investigational compound. Clinical trials have been small and limited to Russia. It is not approved by the FDA or EMA and should only be used in research contexts.

Q: How does Ovagen's cost compare to other reproductive bioregulators?

A: Ovagen typically costs $20-35 per 2mg vial in research settings. This is significantly cheaper than recombinant proteins like follistatin ($100-200/mg) but comparable to other synthetic peptides like ipamorelin or CJC-1295.

Conclusion

Ovagen represents a promising avenue for investigating tissue-specific epigenetic regulation in reproductive aging. As part of Professor Khavinson's broader body of work on bioregulatory peptides, Ovagen offers researchers a tool for studying ovarian senescence, chromatin dynamics, and reproductive tissue restoration. The published evidence, primarily from Russian sources, demonstrates mechanistic plausibility and preliminary efficacy in animal models and small clinical cohorts.

Future research priorities include large-scale Western clinical trials, mechanistic studies of the KED sequence's ovarian-cell specificity, and investigation of combination approaches with established fertility therapies. The peptide's favorable safety profile, ease of synthesis, and tissue-specific targeting make it a valuable research tool in reproductive biology and gerontology.

---

For research purposes only. Not for human use.